A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PBPK / physiologically based PK

[Related PubMed/MEDLINE]
Total Number of Papers: 45
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PBPK  (>> Co-occurring Abbreviation)
Long Form:   physiologically based PK
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling. OATP, PKs, UGT
2023 Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species. ADME, PK
2023 Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants. FDA, PKs, WHO
2023 Quantitative Characterization of Clinically Relevant Drug-Metabolizing Enzymes and Transporters in Rat Liver and Intestinal Segments for Applications in PBPK Modeling. BCRP, DMETs, Mrp, OATP, PK, TPA, UGT
2023 Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. PDs, PKs
2022 Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds. AAFE, AAPE, AFE, CL, ML, PK, Vss
2022 Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. ADME, ASGPR, PD, PK, siRNA
2022 Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. IMPAACT, PK, RDV
2022 Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model. PK, RI, SGLT2, T2DM
10  2022 Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues. devTOX qP, DTP, EADs, IVIVE, LELs, PK, VPA
11  2021 A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. PK
12  2021 Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations. CNS, CSF, ECF, LeiCNS-PK3.0, PK
13  2021 Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. PD, PK, PopPK
14  2021 Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population. NCA, PK
15  2021 Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity. BNP, DIC
16  2021 Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture. DcNP, NHP, PK, TLC-ART
17  2021 Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. DABE, DOACs, PKs
18  2021 Population pharmacokinetic analysis of RO5459072, a low water-soluble drug exhibiting complex food-drug interactions. PK
19  2021 Predicting human pharmacokinetics from preclinical data: volume of distribution. PK, Vd
20  2021 Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy. PK
21  2021 Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. CGNM, PKs
22  2020 A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates. PA, PK, TH
23  2020 Physiologically based pharmacokinetic modelling of lisinopril in children: A case story of angiotensin converting enzyme inhibitors. PK
24  2020 Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. ADME, NPs, PD, PK
25  2020 Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States. DMET, PD, PK
26  2019 A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. AUC, DDIs, PK, TDI
27  2019 Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. CAR, PK-PD, TGI
28  2019 Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis. BCS, IR, IVIVC, PK, PSA
29  2019 Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion. OATPs, PK
30  2018 Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects. ADME, AUC, PKs
31  2017 Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. ADCs, PK
32  2017 Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation. PK
33  2017 Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. PK
34  2017 Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. ---
35  2016 Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels. PK
36  2015 Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research. fuip, fup, PK/PD
37  2015 Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. ADME, FIH, mAbs, PD, PK, TMDD
38  2015 The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. PK
39  2014 Biologics: an update and challenge of their pharmacokinetics. ADA, ADCs, ADME, DI, e.g. Fabs, FcgammaR, mAbs, PK, pop-PK, SMs, TMDD
40  2013 Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. PK
41  2013 Modeling bioavailability to organs protected by biological barriers. PK
42  2012 Pharmacokinetic models for FcRn-mediated IgG disposition. ---
43  2012 Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. ADME, IVIVE, PD, PK
44  2012 Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. AUC, CYP3A4, i.v, PK, TDI
45  2011 The impact of hepatic uptake on the pharmacokinetics of organic anions. PK